Johnson & Johnson
Johnson & Johnson
Explore linked clinical trials.34 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Not yet recruiting | Phase 1 | 2026-10-06 | NCT07860255 | |
| CASTLE-HFpEF (Catheter Ablation for Atrial Fibrillation Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction) | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Not yet recruiting | Not applicable | 2026-10-01 | NCT07254455 | |
| Lumateperone Added to Antidepressant Therapy in Adults With Major Depressive Disorder Experiencing Emotional Blunting | Blunted Emotion in Major Depressive Disorder | Not yet recruiting | Phase 4 | 2026-09-17 | NCT07824206 | |
| REal World MAIA UK OutcomEs | Neoplasms by Histologic Type, neoplasm, plasma cell neoplasm | Not yet recruiting | Not stated | 2026-09-15 | NCT07532473 | |
| Manual Arthroplasty Versus VELYS Robotic-Assisted Solution Functional Alignment Arthroplasty for Knee Osteoarthritis | arthritic joint disease, arthropathy, musculoskeletal system disorder, osteoarthritis, osteoarthritis, knee, rheumatic disorder | Recruiting | Not applicable | 2026-09-11 | NCT07551856 | |
| INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Shock, Cardiogenic, cardiovascular disorder, heart disorder, heart failure, ischemic disease, myocardial infarction, myocardial ischemia, systolic heart failure, vascular disorder | Not yet recruiting | Not applicable | 2026-09-10 | NCT06965504 | |
| Echocardiographic Assessment of the Effect of Impella on Biventricular Function | End-stage Heart Failure | Recruiting | Not stated | 2026-09-09 | NCT07534462 | |
| Teclistamab In Waldenstrom's Macroglobulinemia | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 2 | 2026-09-01 | NCT07791498 | |
| A Prospective, Single-Arm Clinical Evaluation of Visual, Refractive, and Patient-Reported Outcomes Following Bilateral Implantation of the TECNIS PureSee™ Extended Depth of Focus Intraocular Lens | cataract, eye disorder, lens disorder | Not yet recruiting | Phase 4 | 2026-08-27 | NCT07790887 | |
| Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Shock, Cardiogenic, cardiovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Not stated | 2026-08-27 | NCT07655479 | |
| A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-08-17 | NCT07105059 | |
| A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). | Blood Protein Disorders, Hemic and Lymphatic Diseases, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-08-03 | NCT07638683 | |
| A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 3 | 2026-07-31 | NCT07740486 | |
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2026-07-31 | NCT07738887 | |
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level | Blood Protein Disorders, Frailty, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell leukemia, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-07-15 | NCT07649525 | |
| RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF | cardiovascular disorder, heart disorder, heart failure, systolic heart failure | Not yet recruiting | Not applicable | 2026-07-10 | NCT07696975 | |
| Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-05-13 | NCT06993675 | |
| Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Inflammation, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cardiovascular disorder, cytokine release syndrome, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-04-22 | NCT05972135 | |
| Workflow Optimization During Pulse Field Ablation for Atrial Fibrillation | Lidocaine; Pulsed Field Ablation | Not yet recruiting | Phase 4 | 2026-04-20 | NCT07354217 | |
| Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients | Infections, Mediastinal Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Surgical Wound Infection, Thoracic Diseases, Wound Infection, cardiovascular disorder, mediastinitis, respiratory system disorder | Not yet recruiting | Phase 4 | 2026-04-13 | NCT07507409 | |
| DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers | lung disorder, respiratory system disorder | Active, not recruiting | Not stated | 2026-04-01 | NCT04165564 | |
| The Best Workflow for Paroxysmal Supraventricular Tachycardia Ablation With Zero-fluoroscopy | Cardio Vascular Disease; Cryoablation | Enrolling by invitation | Not applicable | 2026-01-22 | NCT07361055 | |
| The Nordic-Baltic Bifurcation Study IV | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Not applicable | 2026-01-02 | NCT01496638 | |
| Emphasys Radiostereometric Analysis | arthritic joint disease, arthropathy, musculoskeletal system disorder, osteoarthritis, osteoarthritis, hip, rheumatic disorder | Recruiting | Not applicable | 2025-12-10 | NCT06173713 | |
| Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Waldenstrom macroglobulinemia, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2025-12-05 | NCT03620903 |